Pfizer on Tuesday said the randomized Phase 2 study met its primary endpoint, showing a 40% reduction in the risk of disease progression or death with a manageable safety profile.
A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival (PFS) in second-line metastatic breast cancer. But ...
Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) ...
– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the ...
Pfizer ( PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results.
NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% ...
The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...
MFDS IND approval enables a multicenter, randomized, double-blind, vehicle-controlled phase 2 study in ~150 DED patients, randomized 1:1:1 to two dosing arms versus control over 12 weeks. Prior phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results